BRK.B
47
-3
DFS
64
2
WEC
29
-5
LRCX
59
3
TRIP
75
9
LNC
43
-2
IR
83
3
DD
48
2
OKE
71
-3
PPL
52
-5
GPS
52
3
CNP
47
-3
BEN
52
10
BXP
47
-3
AVY
77
2
ROK
46
3
IP
33
3
FLS
55
3
UAL
66
8
CINF
41
-9
BRK.B
47
-3
DFS
64
2
WEC
29
-5
LRCX
59
3
TRIP
75
9
LNC
43
-2
IR
83
3
DD
48
2
OKE
71
-3
PPL
52
-5
GPS
52
3
CNP
47
-3
BEN
52
10
BXP
47
-3
AVY
77
2
ROK
46
3
IP
33
3
FLS
55
3
UAL
66
8
CINF
41
-9
Financhill
Back

Y-mAbs Therapeutics 10K Form

Buy
60

YMAB
Y-mAbs Therapeutics

Last Price:
14.68
Seasonality Move:
22.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive YMAB News And Ratings

See the #1 stock for the next 7 days that we like better than YMAB

YMAB Financial Statistics

Sales & Book Value

Annual Sales: $84.82M
Cash Flow: $-8.04M
Price / Cash Flow: 0
Annual Sales: $2.31
Price / Book: 6.65

Profitability

EPS (TTM): -0.49000
Net Income (TTM): $-21.43M
Gross Margin: $73.4M
Return on Equity: -20.49%
Return on Assets: -16.04%

Y-mAbs Therapeutics Earnings Forecast

Key Y-mAbs Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for YMAB is 86.54%.
  • The Selling, General & Administrative Expenses for YMAB have been equal to 52.88% of Gross Profit Margin.
  • The Research & Development expenses have been 63.92% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of YMAB is -25.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Y-mAbs Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: YMAB
CUSIP: 984241
Website: ymabs.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.52
Quick Ratio: 5.02

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

YMAB Technical Analysis vs Fundamental Analysis

Buy
60
Y-mAbs Therapeutics (YMAB) is a Buy

Is Y-mAbs Therapeutics a Buy or a Sell?